Clinical Trials at University of Cincinnati Medical Center
As of August 2026, 73 paid clinical trials are recruiting at University of Cincinnati Medical Center, located at 231 ALBERT SABIN WAY, ROOM 4110, CINCINNATI, OH 45267-0212, phone (513) 558-4592 in Cincinnati, Ohio. Active studies at this site cover conditions such as Heart Failure, Obesity and Overweight. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.
Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: .
Filter results
73 clinical trials at University of Cincinnati Medical Center
·Clear filters·A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
BEATRIX: A Study to Learn About a Group B Streptococcus Vaccine in Healthy Pregnant Women and Their Babies
Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)
A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
A Study to Assess the Long-term Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-3)
A Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-2)
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum Disorder
Multicenter Study of Lumateperone for the Treatment of Bipolar Depression in Pediatric Patients
A Study to Assess Adverse Events and Change in Disease Activity of Oral Icalcaprant in Adult Participants With Bipolar I or II Disorder
A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
DeciPHer-ILD: A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve
Strategy for Improving Stroke Treatment Response
Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)
Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
Pompe Disease Registry Protocol
Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder
Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
A Study to Investigate Subcutaneous Isatuximab in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma
Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors
A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies
A Study to Find Out Whether BI 765423 Has an Effect on Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF) With or Without Standard Treatment
A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosis
(HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis
A Study of Toripalimab in Combination With Cisplatin and Gemcitabine in Participants With Recurrent Metastatic Nasopharyngeal Cancer
A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity
Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint In
Common conditions studied in Cincinnati
- Heart Failure (19 active studies)
- Obesity (19 active studies)
- Overweight (12 active studies)
- Breast Cancer (11 active studies)
- Multiple Myeloma (11 active studies)
- Cystic Fibrosis (10 active studies)
Leading research sponsors in Cincinnati
- Children's Hospital Medical Center, Cincinnati
- University of Cincinnati
- National Cancer Institute (NCI)
- AstraZeneca
- Pfizer
Frequently asked questions
How many paid clinical trials are currently recruiting in Cincinnati?
There are approximately 1,081 recruiting clinical trials in Cincinnati, Ohio listed on ClinicalTrials.gov. The number changes weekly as new studies open and others close enrollment.
Do clinical trials in Cincinnati pay participants?
Most recruiting trials in Cincinnati compensate participants for their time, travel, and study visits. Compensation varies by sponsor, study phase, and visit requirements — the exact amount is disclosed by the study team during the informed consent process.
Who can participate in a clinical trial in Cincinnati?
Eligibility depends on the specific study. Each trial defines its own inclusion criteria (age, diagnosis, medical history, prior treatments) and exclusion criteria. Both patients with specific conditions and healthy volunteers can qualify, depending on the study design.
What conditions are most commonly studied in Cincinnati?
The most common conditions under active study in Cincinnati include Heart Failure (19), Obesity (19), Overweight (12), Breast Cancer (11), among many others. Browse the list above to explore every recruiting trial.
Are there clinical trials for healthy volunteers in Cincinnati?
Yes. Healthy-volunteer studies — often early-phase pharmacology or vaccine trials — recruit in Cincinnati on an ongoing basis. Use the "Healthy volunteers only" filter above to view trials that accept participants without the study's target condition.
How do I enroll in a clinical trial in Cincinnati?
Click any study title above to see the full study record, including eligibility criteria, visit schedule, and the study team's contact information. Reach out to the central contact or recruiting site directly — they will guide you through screening and informed consent.
Where can I take part in paid clinical trials in Cincinnati?
Recruiting research sites in Cincinnati include Cincinnati Children's Hospital Medical Center, University of Cincinnati, University of Cincinnati Medical Center, among others. Each site lists its open studies and contact information on the study record above — call or email the site coordinator to ask about screening for a specific protocol.
What kinds of studies are recruiting in Cincinnati right now?
The largest active categories in Cincinnati are Cancer & tumors (282), Cardiovascular (92), Neurology & pain (73). Use the filters above to narrow by therapeutic area, phase, age, or healthy-volunteer eligibility.
What is the address of University of Cincinnati Medical Center?
University of Cincinnati Medical Center is located at 231 ALBERT SABIN WAY, ROOM 4110, CINCINNATI, OH 45267-0212. Use the Google Maps link in the intro above to get directions.
How do I contact University of Cincinnati Medical Center?
You can reach University of Cincinnati Medical Center by phone at (513) 558-4592. For questions about a specific trial, use the study coordinator contact listed on the individual study record — click any trial title above to open it.